Technologies
PDF


WARF: P00305US

Receptor For Bacillus anthracis Toxin


INVENTORS -

John Young, Kenneth Bradley, R. John Collier, Jeremy Mogridge

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in the structure and sequence of the anthrax toxin receptor.
OVERVIEWInfection with Bacillus anthracis, the spore-forming causative agent of anthrax, can result in either a generally benign, self-limiting cutaneous disease or a more serious and often fatal systemic disease. The serious, systemic form of anthrax results from the inhalation of spores and is caused by anthrax toxin. Because B. anthracis spores can be inexpensively prepared and delivered as an aerosol to cause the deadly inhalation form of infection, B. anthracis spores have become one of the most dreaded agents of biowarfare and bioterrorism.
THE INVENTIONUW-Madison researchers have now provided the structure and sequence of the anthrax toxin receptor. The complete receptor includes an extracellular domain, a transmembrane domain and a cytoplasmic domain that can vary in length.

Identification of the sequence of the anthrax toxin receptor (ATR) will enable the detection and quantification of ATR mRNA and protein in a sample, and will also allow the generation of transgenic and knockout animals. This should lead to methods for treating human and non-human animals suffering from anthrax. For example, the inventors have demonstrated the therapeutic effectiveness of this invention by showing in tissue culture models that a soluble form of the receptor can block anthrax toxin by acting like a decoy.
APPLICATIONS
  • Development of therapeutics to treat anthrax infection
KEY BENEFITS
  • Receptor may be used by pharmaceutical companies to screen for drugs that specifically block anthrax toxin entry by interfering with the toxin-receptor interaction
  • May provide more treatment strategies for anthrax infection
  • Provides a potential cancer target
Contact Information
For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.